ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SNOA vs TNON // FORWARD P/E MULTIPLE

Sonoma Pharmaceuticals Inc. (NASDAQ) VS. Tenon Medical Inc. (NASDAQ) • 15-METRIC TALLY: SNOA 4 — TNON 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNOA VS. TNON) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SNOA TNON SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 38.00% 59.80% -21.80 TNON /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -12.60% -60.00% +47.40 SNOA /operating-margins <GO>
Net Profit Margin 0.00% -60.00% +60.00 SNOA /net-margins <GO>
Revenue Growth (YoY) 36.70% 20.40% +16.30 SNOA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 TNON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.0 38.9 +13.10 SNOA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.7M $6.2M -$411.1K TNON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SNOA REV TNON REV SNOA GROSS % TNON GROSS % SNOA FCF TNON FCF
FY 2025 $19.5M $3.9M 38.0% 59.8% -$4.1M -$11.0M
FY 2024 $14.3M $3.3M 38.2% 52.2% -$168.0K -$10.1M
FY 2023 $12.7M $2.9M — — -$2.4M -$12.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNOA // BETA —
TNON // BETA —